Apogee Therapeutics/$APGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Ticker
$APGE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
196
ISIN
US03770N1019
Website
APGE Metrics
BasicAdvanced
$2.3B
-
-$3.59
-
-
Price and volume
Market cap
$2.3B
52-week high
$50.56
52-week low
$26.20
Average daily volume
1.2M
Financial strength
Current ratio
15.823
Quick ratio
15.726
Long term debt to equity
1.164
Total debt to equity
1.755
Profitability
EBITDA (TTM)
-241.418
Effective tax rate (TTM)
-0.05%
Management effectiveness
Return on assets (TTM)
-19.65%
Return on equity (TTM)
-27.85%
Valuation
Price to book
3.34
Price to tangible book (TTM)
3.34
Price to free cash flow (TTM)
-11.422
Free cash flow yield (TTM)
-8.75%
Free cash flow per share (TTM)
-337.67%
Growth
Earnings per share change (TTM)
25.89%
Bulls say / Bears say
Analysts have set a consensus price target of $93.88 for Apogee Therapeutics, indicating a potential upside of approximately 134% from its current trading price. (nasdaq.com)
The company's lead candidate, APG777, has shown promising interim Phase 1 results for atopic dermatitis, with a notably long half-life that could reduce dosing frequency, potentially offering a competitive advantage over existing treatments. (seekingalpha.com)
Apogee Therapeutics has a robust pipeline targeting significant markets in inflammatory and immunology diseases, including atopic dermatitis, asthma, and COPD, positioning it well for future growth. (stocktitan.net)
Despite positive developments, Apogee Therapeutics reported a net loss of $1.19 per share in its latest earnings report, missing analysts' consensus estimates and raising concerns about its current profitability. (defenseworld.net)
The company's stock has experienced significant volatility, with a 52-week range between $26.20 and $63.50, which may indicate market uncertainty regarding its future performance. (uspostnews.com)
Apogee Therapeutics operates in a highly competitive biotech sector, facing challenges from established players with approved treatments, which could impact its market share and revenue growth. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
APGE News
AllArticlesVideos

Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug
Proactive Investors·4 days ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
GlobeNewsWire·5 days ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apogee Therapeutics stock?
Apogee Therapeutics (APGE) has a market cap of $2.3B as of July 12, 2025.
What is the P/E ratio for Apogee Therapeutics stock?
The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of July 12, 2025.
Does Apogee Therapeutics stock pay dividends?
No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Apogee Therapeutics dividend payment date?
Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Apogee Therapeutics?
Apogee Therapeutics (APGE) does not currently have a Beta indicator.